PTGES3 is a Putative Prognostic Marker in Breast Cancer

2022 ◽  
Vol 271 ◽  
pp. 154-162
Author(s):  
Adeseye Adekeye ◽  
Divyansh Agarwal ◽  
Anupma Nayak ◽  
Julia Tchou
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker

scholarly journals Clinical impact of PTEN methylation status as a prognostic marker for breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Amal Ramadan ◽  
Maha Hashim ◽  
Amr Abouzid ◽  
Menha Swellam
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Prognostic Marker ◽  
Methylation Status ◽  
Clinical Impact ◽  
Breast Cancer Patients ◽  
Duct Carcinoma ◽  
Cancer Group ◽  
And Control

Abstract Background Aberrant DNA methylation of phosphatase and tensin homolog (PTEN) gene has been found in many cancers. The object of this study was to evaluate the clinical impact of PTEN methylation as a prognostic marker in breast cancer. The study includes 153 newly diagnosed females, and they were divided according to their clinical diagnosis into breast cancer patients (n = 112) and females with benign breast lesion (n = 41). A group of healthy individuals (n = 25) were recruited as control individuals. Breast cancer patients were categorized into early stage (0–I, n = 48) and late stage (II–III, n = 64), and graded into low grade (I–II, n = 42) and high grade (III, n = 70). Their pathological types were invasive duct carcinoma (IDC) (n = 66) and duct carcinoma in situ (DCI) (n = 46). Tumor markers (CEA and CA15.3) were detected using ELISA. DNA was taken away from the blood, and the PTEN promoter methylation level was evaluated using the EpiTect Methyl II PCR method. Results The findings revealed the superiority of PTEN methylation status as a good discriminator of the cancer group from the other two groups (benign and control) with its highest AUC and increased sensitivity (96.4%) and specificity (100%) over tumor markers (50% and 84% for CEA and 49.1% and 86.4% for CA15.3), respectively. The frequency of PTEN methylation was 96.4% of breast cancer patients and none of the benign and controls showed PTEN methylation and the means of PTEN methylation (87 ± 0.6) were significantly increased in blood samples of breast cancer group as compared to both benign and control groups (25 ± 0.7 and 12.6 ± 0.3), respectively. Methylation levels of PTEN were higher in the blood of patients with ER-positive than in patients with ER-negative cancers (P = 0.007) and in HER2 positive vs. HER2 negative tumors (P = 0.001). The Kaplan-Meier analysis recognizes PTEN methylation status as a significant forecaster of bad progression-free survival (PFS) and overall survival (OS), after 40 months follow-up. Conclusions PETN methylation could be supposed as one of the epigenetic aspects influencing the breast cancer prognosis that might foretell more aggressive actions and worse results in breast cancer patients.

BTN3A2 serves as a prognostic marker and favors immune infiltration in triple‐negative breast cancer

2019 ◽  
Vol 121 (3) ◽  
pp. 2643-2654 ◽  
Author(s):  
Peian Cai ◽  
Zhenhui Lu ◽  
Jianjun Wu ◽  
Xiong Qin ◽  
Zetao Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Immune Infiltration

scholarly journals 17β-Hydroxysteroid Dehydrogenase Type 1 Is an Independent Prognostic Marker in Breast Cancer

2004 ◽  
Vol 64 (20) ◽  
pp. 7604-7609 ◽  
Author(s):  
Olayiwola O. Oduwole ◽  
Yan Li ◽  
Veli V. Isomaa ◽  
Anne Mäntyniemi ◽  
Anitta E. Pulkka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Hydroxysteroid Dehydrogenase ◽  
Independent Prognostic Marker

scholarly journals The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer

2008 ◽  
Vol 10 (4) ◽  
Author(s):  
Nuran Bektas ◽  
Erik Noetzel ◽  
Jürgen Veeck ◽  
Michael F Press ◽  
Glen Kristiansen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Interferon Stimulated Gene 15

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

2006 ◽  
Vol 12 (8) ◽  
pp. 2468-2475 ◽  
Author(s):  
Grace M. Callagy ◽  
Paul D. Pharoah ◽  
Sarah E. Pinder ◽  
Forrest D. Hsu ◽  
Torsten O. Nielsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Marker ◽  
Prognostic Index ◽  
Nottingham Prognostic Index
Sign in / Sign up

Export Citation Format

Share Document